| Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies (NCT02961101) | Han weidong | 2016-05-01 |
| Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) (NCT02705339) | Washington University School of Medicine | 2016-05-01 |
| A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma (NCT02571829) | Hadassah Medical Organization | 2016-05-01 |
| Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC) (NCT02825628) | DexTech Medical AB | 2016-05-01 |
| MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B (NCT02783833) | Medicines for Malaria Venture | 2016-05-01 |
| Dextran-based Priming vs. Crystalloid and Mannitol-based Priming Solution in Adult Cardiac Surgery (NCT02767154) | Sahlgrenska University Hospital | 2016-05-01 |
| Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme® (NCT02722122) | Protalix | 2016-05-01 |
| 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors (NCT02736448) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2016-05-01 |
| Pro-Change Population Health Solution (NCT02755636) | Pro-Change Behavior Systems | 2016-05-01 |
| A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy (NCT02752048) | Taiho Pharmaceutical Co., Ltd. | 2016-05-01 |
| Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation (NCT02719574) | Forma Therapeutics, Inc. | 2016-04-30 |
| A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension (NCT02742649) | ForSight Vision5, Inc. | 2016-04-30 |
| Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies (NCT02556372) | TaiwanJ Pharmaceuticals Co., Ltd | 2016-04-30 |
| Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome (NCT02710084) | Alexander Kolevzon | 2016-04-29 |
| A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia (NCT02595528) | Allergan | 2016-04-29 |
| A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment (NCT02731690) | Ultragenyx Pharmaceutical Inc | 2016-04-29 |
| A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients. (NCT02712047) | GlaxoSmithKline | 2016-04-29 |
| A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy (NCT02743221) | Institut de Recherches Internationales Servier | 2016-04-29 |
| Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation (NCT02669251) | National Cancer Institute (NCI) | 2016-04-28 |
| Stereotactic Body Radiation for Prostate Oligometastases (NCT02680587) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-04-28 |
| A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema (NCT02699450) | Hoffmann-La Roche | 2016-04-27 |
| Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (NCT02603146) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-04-27 |
| Retention of Potassium From Potatoes and Potassium Gluconate, and the Effect on Blood Pressure. (NCT02697708) | Purdue University | 2016-04-27 |
| A Study of Durvalumab (MEDI4736) in Esophageal Cancer (NCT02639065) | Shadia Jalal, MD | 2016-04-27 |
| Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma (NCT02667886) | X4 Pharmaceuticals | 2016-04-27 |
| Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma (NCT02654990) | pharmaand GmbH | 2016-04-27 |
| A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer) (NCT02387957) | Ophthotech Corporation | 2016-04-26 |
| The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study (NCT02676466) | University of Florida | 2016-04-26 |
| Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone (NCT02806258) | University Hospital, Grenoble | 2016-04-26 |
| Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH (NCT02716246) | Ultragenyx Pharmaceutical Inc | 2016-04-25 |
| A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma (NCT02685826) | Celgene | 2016-04-25 |
| Efficacy and Safety of CD5024 1% in Acne Vulgaris (NCT03034460) | Galderma R&D | 2016-04-25 |
| Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy (NCT02705820) | Bank of Cyprus Oncology Centre | 2016-04-25 |
| Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes" (NCT02671461) | Bristol-Myers Squibb | 2016-04-25 |
| Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients (NCT02763644) | Novartis Pharmaceuticals | 2016-04-22 |
| Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy (NCT02742090) | TG Therapeutics, Inc. | 2016-04-21 |
| Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w/ Body Surface Area (BSA) > 2.0 (NCT02756013) | Case Comprehensive Cancer Center | 2016-04-20 |
| Universal Cancer Peptide-based Vaccination in Metastatic NSCLC (NCT02818426) | Centre Hospitalier Universitaire de Besancon | 2016-04-20 |
| Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NCT02605967) | Novartis Pharmaceuticals | 2016-04-20 |
| FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia (NCT02392429) | National Cancer Institute (NCI) | 2016-04-20 |
| Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas (NCT02636725) | Jonathan Trent, MD, PhD | 2016-04-19 |
| A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease (NCT02713256) | Novartis Pharmaceuticals | 2016-04-19 |
| G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT (NCT02744742) | Nanfang Hospital, Southern Medical University | 2016-04-18 |
| CAP-Ketamine for Antidepressant Resistant PTSD (NCT02655692) | VA Office of Research and Development | 2016-04-18 |
| Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage (NCT02712788) | Indiana University | 2016-04-18 |
| 68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery (NCT02678351) | Andrei Iagaru | 2016-04-18 |
| Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC (NCT02709720) | Spanish Lung Cancer Group | 2016-04-15 |
| Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies (NCT03366350) | Wuhan Sian Medical Technology Co., Ltd | 2016-04-15 |
| Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (NCT02657889) | Tesaro, Inc. | 2016-04-15 |
| Facilitating MAT Acceptance & Implementation in Problem Solving & Felony Courts (NCT03229447) | National Development and Research Institutes, Inc. | 2016-04-15 |
| PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (NCT02624973) | Haukeland University Hospital | 2016-04-15 |
| The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production (NCT03141827) | University Health Network, Toronto | 2016-04-14 |
| The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy (NCT03006081) | Asan Medical Center | 2016-04-14 |
| Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer (NCT02713529) | AmMax Bio, Inc. | 2016-04-14 |
| Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule (NCT02623725) | Sanofi Pasteur, a Sanofi Company | 2016-04-14 |
| Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema (NCT02732951) | Boehringer Ingelheim | 2016-04-14 |
| Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis (NCT02709005) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-04-14 |
| An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) (NCT02610777) | Millennium Pharmaceuticals, Inc. | 2016-04-14 |
| An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread (NCT02658890) | Bristol-Myers Squibb | 2016-04-14 |
| Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction (NCT02695420) | Cytokinetics | 2016-04-14 |
| Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer (NCT02701400) | Emory University | 2016-04-14 |
| Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib (NCT02759835) | National Cancer Institute (NCI) | 2016-04-13 |
| Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) (NCT02573493) | Washington University School of Medicine | 2016-04-13 |
| Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation (NCT02737774) | Henan Cancer Hospital | 2016-04-13 |
| Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease (NCT02633020) | Amgen | 2016-04-13 |
| A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease (NCT02637141) | Amgen | 2016-04-13 |
| A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG) (NCT02742883) | Burzynski Research Institute | 2016-04-13 |
| A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure (NCT02497937) | GlaxoSmithKline | 2016-04-13 |
| Personalized PRRT of Neuroendocrine Tumors (NCT02754297) | CHU de Quebec-Universite Laval | 2016-04-12 |
| Sympathetic and Vascular Function in Takotsubo Syndrome (NCT05768542) | Danderyd Hospital | 2016-04-12 |
| A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients (NCT02691975) | Jiangsu HengRui Medicine Co., Ltd. | 2016-04-12 |
| Fecal Transplant for Hepatic Encephalopathy (NCT03439982) | University of Alberta | 2016-04-12 |
| Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease (NCT03363269) | IlDong Pharmaceutical Co Ltd | 2016-04-12 |
| PEEP and V/Q Mismatch in Premature Infants (NCT03109613) | Children's Hospital of Philadelphia | 2016-04-11 |
| Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer (NCT02535338) | National Cancer Institute (NCI) | 2016-04-11 |
| Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial) (NCT02599922) | Beacon Therapeutics | 2016-04-11 |
| Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp (NCT02838628) | Almirall, S.A. | 2016-04-11 |
| Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma (NCT02532257) | M.D. Anderson Cancer Center | 2016-04-11 |
| Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung (NCT02713828) | PrECOG, LLC. | 2016-04-10 |
| Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer (NCT02630693) | Canadian Cancer Trials Group | 2016-04-08 |
| Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC) (NCT02764125) | Orion Corporation, Orion Pharma | 2016-04-08 |
| Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer (NCT02698891) | Dana-Farber Cancer Institute | 2016-04-07 |
| Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study (NCT02472080) | Assistance Publique - Hôpitaux de Paris | 2016-04-07 |
| Effects of Social Networking on Chronic Disease Management in Arthritis (NCT02717403) | M.D. Anderson Cancer Center | 2016-04-07 |
| Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT (NCT02692248) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2016-04-07 |
| Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma (NCT02760498) | Regeneron Pharmaceuticals | 2016-04-07 |
| Phase II Trial for the Treatment of Relapsed Osteosarcoma (NCT02718482) | Italian Sarcoma Group | 2016-04-06 |
| A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16 (NCT03338556) | Prep Biopharm Limited | 2016-04-06 |
| Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer (NCT02581982) | Wake Forest University Health Sciences | 2016-04-06 |
| Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men (NCT02716675) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-04-06 |
| Risk of Oxygen During Cardiac Surgery Trial (NCT02361944) | Vanderbilt University | 2016-04-05 |
| Second Line Treatment of Knee Osteochondral Lesion With Treated Osteochondral Graft (NCT02430558) | TBF Genie Tissulaire | 2016-04-05 |
| Chemoradiotherapy in Elderly Patients With Oesophagus Cancer (NCT02735057) | Centre Hospitalier Universitaire de Besancon | 2016-04-04 |
| Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease (NCT02685683) | Celgene | 2016-04-04 |
| Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (NCT02726503) | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 2016-04-04 |
| Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors (NCT02717507) | Children's Oncology Group | 2016-04-04 |
| Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies (NCT02504619) | Gamida Cell ltd | 2016-04-04 |
| Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL (NCT02572453) | National Cancer Institute (NCI) | 2016-04-04 |
| Tolerability, Safety and Activity of a Muscle Relaxant Molecule IDN5243 in Patients With Low Back Pain (NCT02568826) | Indena S.p.A | 2016-04-01 |
| Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis (NCT02767297) | Flatley Discovery Lab LLC | 2016-04-01 |